|
|
|
Alexis Crispino
Director of Education & Healthcare Relations
Multiple Sclerosis Association of America (MSAA)
|
|
Mitzi Joi Williams, MD
Founder and CEO
Joi Life Wellness Group, LLC
|
|
Michael Zeglinski, RPh
SVP & CEO
Optum Specialty & Infusion Pharmacies
|
|
TARGET AUDIENCE
|
- The target audience for this activity consists of specialty pharmacy professionals and other managed care and payer professionals.
|
|
PROGRAM OVERVIEW
|
More than a dozen disease-modifying therapies (DMTs) are available for the treatment of MS with several additional novel therapies in late stage development. Early diagnosis and aggressive treatment is essential to minimize the MS disease burden and limit use of limited health care resources. Therefore, a high level of disease and therapeutic knowledge is necessary to effectively and efficiently manage the disease.
The continually evolving MS treatment landscape accentuates the need for increased disease and therapeutic knowledge amongst managed care and specialty pharmacy professionals in order to optimize clinical outcomes, reduce treatment variability, and increase patient engagement in their own care. This program highlights opportunities for managed care and specialty pharmacy professionals to enhance the management of patients with MS by implementing and/or recommending evidence-driven practices and administrative routines based on current clinical trial data.
|
|
EDUCATIONAL OBJECTIVES
|
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
- Discuss where current and emerging therapies fit into the MS management algorithm
- Review the potential impact of and value of real-world evidence to inform clinical decision making in MS
- Explore how to integrate electronic health technology into MS care management
- Employ treatment optimization approaches to balance costs with improved outcomes in MS management
|
|
AGENDA
|
|
12:00 PM
|
Opening Comments/Overview
Michael Zeglinski, RPh
|
|
12:05 PM
|
Assessing the Clinical Benefits of Current and Emerging MS Therapies in a Specialty Pharmacy Setting
Mitzi Joi Williams, MD
|
|
12:35 PM
|
Specialty Pharmacy Management Services for Optimal Outcomes in MS
Michael Zeglinski, RPh
|
|
1:00 PM
|
Shared Decision-Making: Aligning MS Specialty Pharmacy Care with Patient Needs
Alexis Crispino
|
|
1:15 PM
|
Audience Q&A Session
Key Takeaways and Closing Comments
|
|
1:30 PM
|
Adjournment
|
ACCREDITATION INFORMATION
Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Medical Education Resources, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Credit
 |
Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0816-9999-20-138-L01-P
This activity is certified as Knowledge-based CPE.
|
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Faculty |
Reported Financial Relationships |
| Alexis Crispino |
No financial interest/relationships relating to the topic of this activity |
| Mitzi Joi Williams, MD |
Consulting fees (eg. Ad Boards) - Biogen Idec, Genentech, Sanofi Genyzme, Novartis, Abbvie, Bristol Meyers Squibb
Speakers' Bureaus - Biogen Idec, Genentech, Genzyme, Bristol Meyers Squibb, TEVA |
| Michael Zeglinski, RPh |
Salary - Optum; UPMC Medical Center |
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
| Name of Content Manager |
Reported Financial Relationships |
| Impact Education, LLC. Content Managers |
No financial interest/relationships relating to the topic of this activity |
| MER Content Managers |
No financial interest/relationships relating to the topic of this activity |
Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.
Fee Information
There is no fee for this educational activity.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
If you have any questions, please call (215) 619-8812 or email info@impactedu.net.
| | | | |
